4160117/2025 - Alpha-1 antitrypsin (Respreeza) (awaiting centralized aggregation by SPMS)

This tender, referenced as 4160117/2025, concerns the procurement of "Alpha-1 antitrypsin (Respreeza)". Alpha-1 antitrypsin is a protein that protects the lungs from damage. "Respreeza" is a specific brand name for an Alpha-1 antitrypsin augmentation therapy used to treat individuals with Alpha-1 antitrypsin deficiency. The note "awaiting centralized aggregation by SPMS" indicates that the procurement process is pending or coordinated through SPMS (Serviços Partilhados do Ministério da Saúde - Shared Services of the Ministry of Health), a central entity in Portugal responsible for shared services within the Ministry of Health. This suggests a centralized procurement strategy to ensure efficient and potentially cost-effective acquisition of this specialized medication. The tender is likely for the supply of this medication, possibly in significant quantities, to be distributed to relevant healthcare providers or patients. Potential bidders would be pharmaceutical manufacturers or authorized distributors of "Respreeza". The tender documents would specify the required quantities, dosage, delivery terms, and any specific regulatory or quality assurance requirements. The objective is to ensure the availability of this life-saving therapy for patients diagnosed with Alpha-1 antitrypsin deficiency.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 18,612.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.